Big Move For Monopar Therapeutics Inc.

Monopar Therapeutics Inc. (MNPR:NASDAQ) soared at $1.12, a gain of 96.5%. On Thu, Feb 22, 2024, MNPR:NASDAQ touched a New 2-Week High of $1.12. The stock got featured on our News Catalysts scanner on Thu, Feb 22, 2024 at 08:25 AM in the 'BIOTECH' category. From Thu, Feb 08, 2024, the stock recorded 44.44% Up Days and 20.00% Green Days

The stock spiked on Tue, Feb 20, 2024 at $1.56 with a volume of 100M+.

About Monopar Therapeutics Inc. (MNPR:NASDAQ)

Monopar Therapeutics Inc is the United States-based clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to improve clinical outcomes for cancer patients. Its pipeline products comprise of Validive, Camsirubicin, and MNPR-101.